Schrodinger, Inc. (SDGR): Results of Operations and Financial Condition
Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sdgr-20260630x8kxexx991.htm EX-99.1 Document Exhibit 99.1 Schrödinger Reports Second Quarter 2026 Financial Results Second Quarter ACV of $30 Million, Representing 27% Growth Launched Early Access Version of Bunsen, A New Agentic AI Co-Scientist for Molecular Discovery
How this was made
The 30-second read
Why it matters
Key tradable items are the updated ACV and drug discovery revenue guidance ranges, the driver being the $10M Ajax collaboration milestone, and the shift toward hosted software licensing with higher software gross margin.
Market read
Traders can update models immediately using the raised FY drug discovery revenue range and the ACV growth trajectory, with a clear milestone-based explanation.
What to watch
Other income surged due to a gain tied to Eli Lilly completing the Ajax acquisition, which may not be repeatable; traders may focus on operating performance excluding investment gains.
Background
This is an SEC 8-K (Item 2.02) with Q2 2026 results and updated FY 2026 guidance, plus product and customer/collaboration updates around Bunsen.
Ticker impact
Schrodinger reported Q2 2026 ACV of $29.6M (+27%) and raised FY drug discovery revenue guidance to $65M-$75M.
Likely positive near-term bias as traders reprice FY drug discovery revenue and ACV growth trajectory.
The filing is a primary disclosure (8-K) with specific quarterly results and updated full-year guidance, including a clear driver (Ajax milestone) and improving operating metrics (operating expenses down, software gross margin 71%).
Market effects
Reinforces demand for physics-based simulation plus agentic AI in molecular discovery, supporting sentiment for computational drug discovery software.
Limited, primarily US-listed biotech/AI software sentiment.
Moderate, as collaborations with large pharma (BMS) and global cloud/AI partners signal broader enterprise adoption.
Counterpoint
Software revenue declined 10% year over year, so the market may question whether hosted transition and ACV growth fully offset near-term revenue mix pressure.
Key entities
- companySchrodinger, Inc.
Nasdaq-listed computational molecular discovery company reporting Q2 results and FY 2026 guidance.
- productBunsen
Agentic AI co-scientist early access version for molecular discovery workflows.
- customer_partnerBristol Myers Squibb
Strategic software agreement to deploy Bunsen across its research organization.
- collaboration_partnerSimcere Pharmaceutical Group
Global drug discovery and development collaboration for an unmet clinical-need program.
- transaction_partnerEli Lilly and Company
Completion of acquisition of Ajax Therapeutics drove a gain in other income.